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ABSTRACT
Prostate cancer has become one of the most common malignancy in men worldwide including Asia. Its incidence in
Asia is lower compared to western countries, however currently there is an increasing trend of the incidence in the
developing countries. Digital rectal examination, PSA and TRUS guided biopsy are still the standard diagnostic
methods despite the fact that there are still a high percentage of patients who undergo TUR-P for diagnostic purposes.
Treatment options for an early stage prostate cancer consists of radical prostatectomy from open to robotic, and
radiotherapy. Most patients usually come with an already advanced stage and the treatments commonly done are
hormonal therapy and TUR-P. Even in the early stage cases, radical treatment measures are still rarely done due to lack
of treatment facilities (radiotherapy machine) or manpower (capable for radical prostatectomy). These problems could
be overcome by having more manpower, medical facilities, and patient education campaign.
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ABSTRAK 
Kanker prostat adalah salah satu keganasan yang paling sering ditemukan pada pria di seluruh dunia, termasuk Asia.
Insiden kanker prostat di Asia lebih rendah dibandingkan dengan negara-negara barat, tetapi saat ini terdapat
kecenderungan peningkatan insiden di negara-negara berkembang. Walaupun colok dubur, PSA, dan biopsi prostat
dengan bimbingan TRUS masih merupakan metode diagnostik standar, masih banyak ahli urologi yang menggunakan
TUR-P sebagai metode diagnostic, terutama di negara-negara berkembang. Pilihan terapi untuk kanker prostat stadium
dini terdiri dari prostatektomi radikal, baik secara terbuka maupun robotik dan radioterapi. Kebanyakan pasien datang
dengan kanker prostat stadium lanjut dan terapi yang diberikan adalah hormonal dan TUR-P. Pada beberapa kasus
stadium dini, terapi radikal juga masih jarang dikerjakan. Hal ini disebabkan oleh kurangnya fasilitas (mesin radioterapi)
atau tenaga ahli yang dapat mengerjakan prostatektomi radikal secara baik. Masalah-masalah ini dapat diatasi dengan
memperbanyak tenaga ahli, fasilitas medic, dan edukasi pasien.
Kata kunci: Prostat, kanker, asia.
INTRODUCTION
Prostate cancer has become one of the most common malignancy in men worldwideincluding Asia although with lower incidence compared to western countries.1 In the last
ten years more publications on prostate cancer from various Asian countries have appeared in
medical journals or conference reports. From these studies we understand that the incidence
of prostate cancer in this region has increased.2,3 The purpose of this study is to know the
recent incidence, diagnostic procedure, and treatment modality of prostate cancer in Asia.
METHODS
Pubmed search and other related sources using keywords: prostate cancer, diagnostic
method, treatment option and Asia were collected and analyzed.
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than 4 ng/ml and increasing to more than 30% in group
with PSA above 20 ng/ml.6,7
Regarding the stage, it is typical that the advanced
stage prostate cancer is more common in developing
countries (61-73%) compared to in developed countries
such as in Singapore, Taiwan, S. Korea (11-33%).8
Recently, radical prostatectomy (RP) is a common
procedure for organ confined prostate cancer in many
urological center throughout Asia. Even the robot-
assisted laparoscopic RP became a standard procedure in
some centers in many Asian countries. In other centers, it
will be done as pure LRP or open surgery. 
There are not so many Asian publication concerning
the use of external beam radiotherapy (EBRT) for
definitive treatment of prostate cancer although a more
sophisticated facility such as intensity-modulated
radiation therapy (IMRT) machines are available in
Thailand, Indonesia, Japan, India, Singapore, Malaysia, S.
Korea, Hong Kong and many other Asian countries.9,10
Hormonal treatment is the mainstay for advanced
stage patients. Bilateral orchyectomy is a more popular
method, even DES tablet still being used in some country
due to economical reason. However, utilization of LHRH
injection becomes more often especially by including this
drug in government besides private insurance coverage.
Besides for advanced disease, LHRH injection is also
routinely given as neo-adjuvant androgen deprivation
treatment before radiotherapy in T3 cases or as adjuvant
treatment in patients with node positive after RP or high
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RESULTS
Incidence of prostate cancer has increased between 5-
120% in the last ten years with Singapore (Chinese), Japan
(Miyagi), China (Shanghai), and the Philippines (Rizal) as
the countries being the highest. According to Globocan
2002 report, the incidence rate of prostate cancer in Asia
varies from 0.3 in Bangladesh and 18.6 in the Philippines
which was lower compared to the Western world.3,4
Besides digital rectal examination (DRE), prostate
specific antigen (PSA) measurement has become a
standard procedure in many urological clinic to determine
the need of prostate biopsy. The cut-off level of PSA as a
biopsy indication varies from country to country;
although many centers used 4 ng/ml or even lower as
indication for biopsy,  some countries still used 10 ng/ml
or higher as cut-off level.5
Mean age at diagnosis varies between 66-72 years
without clear difference between developed or
developing Asian countries. However, mean PSA at
diagnosis was lower in developed countries such as Japan
and S. Korea which was between 15-51 ng/ml, while in
developing countries it varies from 75-373 ng/ml.6
Diagnostic  of  prostate cancer was mainly done with
TRUS guided biopsy; this procedure was more common
in developed countries ranging from 75-89% compared to
26-74% in other countries (Table 1). Table 2 shows the
correlation between PSA and prostate cancer detection
rate in several Asian countries. In some of the countries,
this rate was extremely low in population with PSA less
Table 1:  Prostate cancer in Asia: Diagnostic methods (%) 
Author Country Biopsy TUR-P Open Others
Ahmad Z et al, 200921 Pakistan 26 74 n.a n.a
Peyromaure M et al 200522 China 68 5 1 26
Umbas R, 200523 Indonesia 66.5 29.9 3.6 0
Akaza H et al, 20038 Singapore 75 20 0 5
Akaza H et al, 20038 Taiwan 77 17 0 6
Cancer Reg JUA, 200515 Japan 89 n.a n.a n.a
Table 2: Prostate cancer detection rate by TRUS guided biopsy (%)
Author Country n PSA (ng/ml)
0-4 4.1-10 10.1-20 20.1-50 >50
Dai B et al, 20087 China 221 3.7 6.9 22.2 69.6 95.2
Chin JL et al, 200924 China 540 14.3 14.9 20.3 39.3 89.3
Chavan PR et al, 200925 India 922 0.6 2.3 2.5 34.1 54.9
Seo HK et al, 20076 S. Korea 4967 13.4 19.6 34.0 76.0 n.a
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grade tumor following EBRT as suggested by many
guidelines.5
DISCUSSION
As a continent, Asia consists of many different
countries with their own cultures, diet,  health status,
environment, and economical situations. The incidence of
prostate cancer in Asia is lower compared to western
countries. However, currently there is a decreasing
tendency of the incidence in United States and other
western countries as opposed to an increasing trend of
the incidence in Asia and other developing countries
probably because of adoption of unhealthy western
lifestyles such as smoking and physical inactivity and
consumption of calorie-dense food.11
Some of the common risk factors are increasing life
expectancy resulting in more men older than 70 years,
westernized diet habit, and environmental exposure.
With the projected increase of 300% more elderly
population in Asia, one can expect that the incidence of
prostate cancer in this region will be more prominent due
to the fact that prostate cancer is more common in older
population.12-15 In contrast, there are also some
evidences that certain diet such as soy and green tea
could be linked to the relatively low incidence of prostate
cancer in many Asian countries. However, according to
the latest Cochrane review, results from several studies on
the role of green tea (Camellia sinensis) should be
considered as insufficient and conflicting, so at this
moment no firm recommendation could be taken
regarding green tea consumption for prostate cancer
prevention.16
TRUS guided biopsy is a standard diagnostic method
for prostate cancer. In developing countries such as in
Asia, there are still a high percentage of patients who
underwent TUR-P for diagnostic purposes. However, the
number of biopsies taken were almost similar with
average 8 to 12 cores as reported in recent studies.7,17,18
TUR-P is still frequently done by urologists in developing
countries probably due to lack of diagnostic equipment
(TRUS probe and needle) or the patients had already
come with urinary retention. 
Many urological clinics in Asia are still using PSA more
than 10 ng/ml as a cut-off level for the indication to do a
prostate biopsy. This policy is usually based on their own
experiences with low biopsy positive rate in patients with
PSA less than 10 ng/ml.19
Patients usually come with an already advanced stage
in developing countries. These figures could be due to
patients ignorance, but could also reflect the shortage of
manpower and/or medical instrument including TRUS
probe to perform prostate biopsy as an effort for early
diagnosis. Thus, regarding treatments, hormonal therapy
and/or TUR-P are frequently chosen by urologists.
Unfortunately for the early stage patients, the number of
radical treatment measures such as radical prostatectomy
and radiotherapy being done are also still low. Lack of
treatment facilities (radiotherapy machine) or manpower
(capable for radical prostatectomy) may be the cause
behind those numbers. In general RP will be indicated in
patient with life expectancy > 10 years; of course it
depends from country to country, for example age limit
for RP was set at 75 years by 66-69% of urologists in a
Japanese survey.20 According to several studies,
hormonal therapy has also been given as primary
treatment in young age patients with organ confined
disease. It is not clear whether this treatment was
suggested by the urologist or patient driven.5
Taken together, these trends mentioned above will end
up in a low number of newly detected prostate cancer
and possibly under or over treatment of prostate cancer
patients in our country.
CONCLUSIONS
The incidence of prostate cancer in Asia is increasing
and with an increase of elderly population in the future, it
is clear that this disease will become more prominent.
Currently, the diagnostic procedure is not yet uniform. In
some countries, one third of prostate cancer was
diagnosed not by prostate biopsy. There was also a huge
variation in tumor stage which show that in some Asian
countries, prostate cancer patients were diagnosed with
advanced disease. These problems could be overcome by
having more manpower, medical facilities, and patient
education campaign. Despite these situations, many
Asian urologists have already embarked to laparoscopic
technique of RP, even robotic machines are already
available in several countries. v
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